Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.

Jifang GongJunning CaoQingyuan ZhangNong XuYanqiu ZhaoBaocai XingZhanhui MiaoYilong WuHongming PanQuanli GaoXingya LiBaorui LiuWei LiZhidong PeiHongqiang XiaQinzhou QiHangjun DaiQingmei ShiJianxin YangJin LiLin Shen

Published in: Cancer immunology, immunotherapy : CII (2022)

Sugemalimab was well-tolerated and showed promising antitumor activity as monotherapy or in combination with SOC chemotherapy in advanced malignancies. This trial was registered with ClinicalTrials.gov on Oct 18, 2017, number NCT03312842.

Keyphrases

endothelial cells
phase iii
study protocol
clinical trial
open label
optical coherence tomography
induced pluripotent stem cells
phase ii
pluripotent stem cells
locally advanced
combination therapy
diabetic retinopathy
optic nerve